INTRODUCTION {#sec1-1}
============

Rheumatoid arthritis is the most common inflammatory arthritis affecting 0.5 to 1% of general population worldwide.[@ref1] Nonalcoholic fatty liver disease (NAFLD) is defined as the abnormal accumulation of fats (liver fat\>5-10% of liver weight), primarily in the form of triglycerides in those with daily use of alcohol (≤ 20 g ethanol/d), disease spectrum ranges simple steatosis to steato-hepatitis with fibrosis, scarring, ultimately leading to cirrhosis, with worldwide prevalence of (10-40%).[@ref2],[@ref3]

Liver injury is not considered as major extra-articular feature of RA but abnormal liver tests fluctuating with disease activity, mainly elevated alkaline phosphatase, have been seen in 18 to 50% cases.[@ref4] Ruderman et al in retrospective study on 188 autopsy cases of RA found, 65% of unselected patients with RA had abnormal liver biopsies one-half having mild portal chronic inflammatory infiltrate of the portal tract and small foci of necrosis, and one in four having fatty liver changes.[@ref5]

Shunshuke Mori et al in their observational study of 846 RA found that 42 patients using methotrexate had persistent elevation of transaminases while ultrasound showed fatty liver disease and histological results revealed nonalcoholic steato-heapatitis as most prevalent pattern of liver injury, there was no significant impact of methotreaxte dose and duration on histological severity.[@ref6]

Systematic review by Salliot and van der Heijde identified increased levels of transaminases (ALT, AST) as the second most frequent adverse effects with methotrexate therapy (20.2%) after gastrointestinal probelms.[@ref7] I t is found that fatty liver disease (NAFLD), diagnosed either by imaging or biopsy, has been associated with methotrexate therapy since long.[@ref8]-[@ref10]

Rajalingham S, et al, in their observational study found that MTX associated NAFLD prevalence was 4.7% and MTX dose was only independent predictor of MTX associated NAFLD with transaminitis.[@ref11] Our objective was to determine the frequency of fatty liver (non-alcoholic) disease, Framingham 10-year cardiovascular risk score in rheumatoid arthritis patients

METHODS {#sec1-2}
=======

After the approval of Institutional review board, (CPMC/IRB/1725, Dated: 10-09-2018), cross sectional study was conducted at rheumatology division department of medicine central park medical college Lahore. Written and informed consents were taken from each study participant after informing and assuring the confidentiality of their data. Sample size of 192 was calculated by using openepi sample size calculator after inserting 4.7% prevalence of MTX associated NAFLD (at 3% margin of error and (95% CI).

Seropositive patients with history of illness for more than one year and those who never had used alcohol in their life were included. Known cases of sero-negative RA, SLE, MCTD, SSc, SjS, psoriatic arthritis, diagnosed cases of hypothyroidism, primary biliary cirrhosis, cardiac cirrhosis, Wilson disease, hemochromatosis, using lipid lowering agents, acute liver disease, chronic liver diseases like cirrhosis and malignancy, current or past use of antiviral therapy for chronic hepatitis (B,C,) & HIV were excluded.

Demographic parameters were asked in detail like age, disease duration, number of medicine in use ,smoking habits, hakeem/Desi medication use for 6 months or more in past two years, history of blood pressure and medicines in use noted, DM was inquired along with insulin or oral hypoglycemic medicines use, waist circumference was measured by standardized formula, circumference of more than 80cms in females and more 90 cms in males taken as criteria point as per International diabetes federation, Blood pressure was measured after mandatory 5 minutes rest, best of two was noted. All study participants were examined by a consultant physician in detail for clinical stigmata of acute and chronic liver diseases and comorbid conditions.

All study participants underwent abdominal ultrasonography for detection of NAFLD as per radiological criteria, (Bright hepatic echoes, increased hepato-renal echogenicity and vascular blurring of portal or hepatic vein have been classified as unique sonographic features of NAFLD[@ref12] by an expert sonographer having 10 years' experience, participant(s) with feature(s) of chronic liver disease were found were excluded ,all study participants were requested to return back on next morning with 14 hours fasting state,5 ml of blood was taken with aseptic techniques by a trained phlebotomist, samples were sent to laboratory for FBS, Lipid profile and liver enzyme levels on COBAS-III machine.

After availability of lab results Metabolic syndrome was defined as per IDF criteria[@ref13] (1) waist circumference \>80cms females and \>90 males, (2) HDL levels of \<50mg females and \<40mg males or on treatment with lipid lowering treatment, (3) TG levels of \>150mg (4) diagnosed hypertension or treatment of hypertension, BP\>130mmhg or diastolic BP \>85mmhg (5) FBS 100 mg /dl or more or on treatment of diabetes mellitus, if anyone have 2 out of five, with waist circumference of more than reference range were labeled as metabolic syndrome, their 10-years FRS cardiovascular risk was calculated by Framingham risk calculator by putting values like age, sex, systolic BP, using antihypertensive Medicines, smoking habits, diabetes, and HDL levels, individuals were categorized into FRS \<10% score=mild, 11-20%=moderate risk, risk\>20% = severe. Data was stored and analyzed using IBM SPSS version 23.0.

RESULTS {#sec1-3}
=======

In this study, prevalence of fatty liver disease (NAFLD) was n=39(20.3%). Female gender was predominant (81.3%), majority belonged to age group 31-40 years (32.3%). Over all use of MTX and other DMARD's was seen in (72%) cases. Hakeem/desi medications use (29.7%), smokers (14.6%), MeTS (31.8%), Hypertension (31.8%), DM (14.1%), FRS between 10-20 as intermediate risk (11.9%). [Table-I](#T1){ref-type="table"}. [Fig-1](#F1){ref-type="fig"}.

###### 

Baseline Characteristics of Studied Samples (n= 192).

  Characteristics             n               \%     
  --------------------------- --------------- ------ ------
  Age Group                   20 - 30 years   44     22.9
  31 - 40 years               62              32.3   
  41 - 50 years               61              31.8   
  \>50 years                  25              13.0   
  Gender                      Female          156    81.3
  Male                        36              18.8   
  Medication Use              MTX             95     49.5
  MTX+HQ                      28              14.6   
  MTX+HQ+SSZ                  44              22.9   
  LEF                         14              7.3    
  CS ALONE                    11              5.7    
  Fatty Liver                 Yes             39     20.3
  No                          153             79.7   
  HAKEEM/DESI Medication      Yes             57     29.7
  No                          135             70.3   
  Smoking                     Yes             28     14.6
  Ex-Smoker                   2               1.0    
  No                          162             84.4   
  MeTS                        Yes             61     31.8
  No                          131             68.2   
  Hypertension                Yes             61     31.8
  No                          131             68.2   
  DM                          Yes             27     14.1
  No                          165             85.9   
  FRS                         \<10 Low Risk   110    72.8
  10 - 20 Intermediate Risk   18              11.9   
  \>20 High Risk              23              15.2   

![Associated Factors of Fatty Liver Diseases](PJMS-36-723-g001){#F1}

In RA patients with fatty l ver (n=39) females were n=25 (64.1%), MTX use (48.7%), Hakeem/Desi medication use (51.3%), MeTS (71.8%), hypertension (59%), DM (33.3%), high FRS (33.3%), all other parameters except MTX use had significant association with fatty liver disease (P.05) [Table-II](#T2){ref-type="table"}.

###### 

Association of Fatty Liver with Studied Parameters.

  Factors                     Fatty Liver     p-value                        
  --------------------------- --------------- --------- ------ ------ ------ ----------------------------------------
  Gender                      Female          25        64.1   131    85.6   \<0.01[\*](#t2f1){ref-type="table-fn"}
  Male                        14              35.9      22     14.4          
  Medication Use              MTX             19        48.7   76     49.7   0.09
  MTX+HQ                      4               10.3      24     15.7          
  MTX+HQ+SSZ                  6               15.4      38     24.8          
  LEF                         6               15.4      8      5.2           
  CS ALONE                    4               10.3      7      4.6           
  HAKEEM/DESI Medication      Yes             20        51.3   37     24.2   \<0.01[\*](#t2f1){ref-type="table-fn"}
  No                          19              48.7      116    75.8          
  Smoking                     Yes             11        28.2   17     11.1   0.02[\*](#t2f1){ref-type="table-fn"}
  Ex-Smoker                   0               0.0       2      1.3           
  No                          28              71.8      134    87.6          
  MeTS                        Yes             28        71.8   33     21.6   \<0.01[\*](#t2f1){ref-type="table-fn"}
  No                          11              28.2      120    78.4          
  Hypertension                Yes             23        59.0   38     24.8   \<0.01[\*](#t2f1){ref-type="table-fn"}
  No                          16              41.0      115    75.2          
  DM                          Yes             13        33.3   14     9.2    \<0.01[\*](#t2f1){ref-type="table-fn"}
  No                          26              66.7      139    90.8          
  FRS                         \<10 Low Risk   20        51.3   90     80.4   \<0.01[\*](#t2f1){ref-type="table-fn"}
  10 - 20 Intermediate Risk   6               15.4      12     10.7          
  \>20 High Risk              13              33.3      10     8.9           

p\<0.05 was considered significant using Pearson Chi Square test.

The mean of different study parameters were, mean age 45.44 (±7.2), mean ALT 83.38 (±35.4), mean AST 71.7 (±29.1), mean HDL 41.8 (±57.8), mean cholesterol 205 (±31.1), mean TG 169.03(±32.5), mean FBS 116.33(±32.5), mean SBP 133.90 (±15.11), mean DBP 85.13 (±7.0) mean, WC 91.33 (±1.5) cms and mean FRS was 16.43 (±17.9). There were significant mean differences obtained between two studied groups with (\<p.05). [Table-III](#T3){ref-type="table"}.

###### 

Mean Comparison of Quantitative Parameters.

  Parameters    Total    Fatty Liver   p- value                            
  ------------- -------- ------------- ---------- ------- -------- ------- ----------------------------------------
  Age (Years)   39.97    10.55         45.44      7.23    38.58    10.82   \<0.01[\*](#t3f1){ref-type="table-fn"}
  ALT           46.94    31.69         83.38      35.42   37.65    22.82   \<0.01[\*](#t3f1){ref-type="table-fn"}
  AST           41.66    25.21         71.74      29.10   33.99    17.18   \<0.01[\*](#t3f1){ref-type="table-fn"}
  ALP           117.27   25.35         123.49     24.70   115.68   25.35   0.08
  HDL           48.43    7.88          41.85      7.82    50.10    6.99    \<0.01[\*](#t3f1){ref-type="table-fn"}
  Cholesterol   188.09   30.65         205.00     31.17   183.78   29.08   \<0.01[\*](#t3f1){ref-type="table-fn"}
  TG            146.45   27.86         169.03     32.57   140.69   23.37   \<0.01[\*](#t3f1){ref-type="table-fn"}
  FBS           101.90   22.72         116.33     31.91   98.22    18.07   \<0.01[\*](#t3f1){ref-type="table-fn"}
  SBP           126.26   14.77         133.90     15.11   124.31   14.08   \<0.01[\*](#t3f1){ref-type="table-fn"}
  DBP           81.82    8.07          85.13      7.02    80.98    8.13    \<0.01[\*](#t3f1){ref-type="table-fn"}
  WC            83.07    11.31         91.33      11.55   80.97    10.27   \<0.01[\*](#t3f1){ref-type="table-fn"}
  FRS           9.88     13.83         16.43      17.91   7.60     11.32   \<0.01[\*](#t3f1){ref-type="table-fn"}

p\<0.05 was considered significant using Independent sample t-test.

Odds ratio for associated risk factors with fatty liver diseases obtained using binary logistic regression results showed, old age, male gender, high score of FRS, use of Homeopathic medication, smoking, MeTS, hypertension, diabetes and aminotransferases gives significant positive association in cases found with higher risk of fatty liver diseases. Use of methotrexate and different combination of treatments in RA given less association with fatty liver disease. [Table-IV](#T4){ref-type="table"}. Prevalence of various study metabolic factors in fatty liver positive group is shown in (Bar chart).

###### 

Estimation of Odds Ratio with 95% confidence interval for Risk of Fatty Liver Disease.

  Risk Factors                Odds Ratio (95% C.I)   p-value                                  
  --------------------------- ---------------------- ---------------------------------------- ----------------------------------------
  Age Group                   20 - 30 years          Reference                                
  31 - 40 years               10.3(1.2-82.6)         0.02[\*](#t4f1){ref-type="table-fn"}     
  41 - 50 years               18.0(2.3-140.8)        \<0.01[\*](#t4f1){ref-type="table-fn"}   
  \>50 years                  20.2(2.3-174.3)        \<0.01[\*](#t4f1){ref-type="table-fn"}   
  Gender                      Female                 Reference                                
  Male                        3.35(1.5-7.3)          \<0.01[\*](#t4f1){ref-type="table-fn"}   
  Medication Use              CS ALONE               Reference                                
  MTX                         0.43(0.11-1.65)        0.22                                     
  MTX+HQ                      0.29(0.05-1.47)        0.13                                     
  MTX+HQ+SSZ                  0.27(0.06-1.23)        0.93                                     
  LEF                         1.31(0.25-6.64)        0.74                                     
  FRS                         \<10 Low Risk          Reference                                
  10 - 20 Intermediate Risk   2.25(0.74-6.71)        0.14                                     
  \>20 High Risk              5.85(2.24-15.2)        \<0.01[\*](#t4f1){ref-type="table-fn"}   
  HAKEEM/DESI Medication      Yes                    3.30(1.59-6.84)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  Smoking                     Yes                    3.09(1.30-7.32)                          0.01[\*](#t4f1){ref-type="table-fn"}
  MeTS                        Yes                    9.25(4.17-20.53)                         \<0.01[\*](#t4f1){ref-type="table-fn"}
  Hypertension                Yes                    4.35(2.08-9.08)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  DM                          Yes                    4.96(2.09-11.7)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  Duration of RA              Yes                    1.06(0.99-1.15)                          0.08
  ALT                         Measured               1.04(1.03-1.06)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  AST                         Measured               1.05(1.04-1.07)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  ALP                         Measured               1.01(0.99-1.02)                          0.09
  HDL                         Measured               0.84(0.79-0.89)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  Cholesterol                 Measured               1.02(1.0-1.03)                           \<0.01[\*](#t4f1){ref-type="table-fn"}
  TG                          Measured               1.03(1.02-1.04)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  FBS                         Measured               1.02(1.01-1.04)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  SBP                         Measured               1.04(1.01-1.07)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  DBP                         Measured               1.06(1.02-1.12)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  WC                          Measured               1.08(1.04-1.12)                          \<0.01[\*](#t4f1){ref-type="table-fn"}
  FRS                         Measured               1.04(1.01-1.07)                          \<0.01[\*](#t4f1){ref-type="table-fn"}

p\<0.05 was considered significant for odds ratio.

DISCUSSION {#sec1-4}
==========

There is lack of understanding how NAFLD develops in RA patients. Few proposed mechanisms are folate deficiency, high cell turnover, deficiency of purines, pyrimidine thymidine, methionine and accumulation of MTX polyglutamates with genetic polymorphisms in MTX metabolism like C677T polymorphism, increases the chances of its toxicity.[@ref14]-[@ref17] In our study prevalence of NAFLD was 20.3% (n=39) while in study Rajalingham et al.[@ref11] it was (4.7%) but MTX and other DMARDs association was not established likewise in our study also.

Shunsuke Mori et al.[@ref6] and Quintin et al.[@ref18] in biopsy results of 41 and 32 patients with arthritis on low dose MTX found non-alcoholic steatohepatitis as most frequent lesion, similarly their studies also didn't established the association of lesions with Methotrexate use.

Ruderman et al.[@ref5] and Shunshuke et al.[@ref6] reported that fatty, NASH like lesion or fibrosis exited before the start of MTX introduction. Kuo-Tung Tang et al in their study on chronic hepatitis B and RA patients treated with MTX for 97 months didn't resulted in development of Cirrhosis.[@ref19]

In a very recent study by Ursini et al found NAFLD prevalence of (25%) and suggested complement factor C3 as potential biomarker for NAFLD.[@ref20] In a meta-analysis conducted by Young-Ho lee et al about genetic association of NAFLD in RA and psoriatic arthritis found that PPARg Pro12Ala polymorphism is associated with susceptibility to NAFLD in East Asians, but not in European populations.[@ref21] In Chinese study on general population fatty liver prevalence was (24.7%) with strong association of certain metabolic traits like, higher body fat, obesity, dyslipidemia raised fasting blood sugar levels.[@ref22]

There is well known perception that metabolic syndrome precedes the development of NAFLD and considered as the hepatic manifestation of metabolic syndrome, but A. Lonardo et al, found reverse is true NAFLD precedes the metabolic syndrome, as insulin resistance is present in majority of cases but only minority develops metabolic syndrome, and it has strong association with type 2 diabetes mellitus while these subjects are 1.6 times more likely develop diabetes than NAFLD free cases.[@ref23] In our study NAFLD positive group (n=39) the prevalence of metabolic syndrome was 71.3% (n=28).

Rheumatic disorders are associated with overexpression of the pro inflammatory cytokine (TNFα), and these disorders respond to treatment with TNF inhibitors (TNFi). TNFα also appears to be a key mediator of fatty liver disease and hepatic fibrosis, so (TNFi) has been proposed as a potential therapeutic target for patients with NASH. Data suggest that TNFi treatment might prevent NAFLD, but there were number of patients with immune-mediated inflammatory diseases to develop NAFLD during treatment with TNFi, which resolved when therapy was stopped.[@ref24]

Sombat Treeprasertsuk et al.[@ref25] reported that in patients with NAFLD there is higher Framingham cardiovascular risk score than general population, our study results also showed that NAFLD positive group had higher FRS score with mean score of (16.4) while mean score in NAFLD negative group was (9.8), and almost half of the positive group study participants FRS score was in intermediate to high risk scores. Interestingly in our patients with NAFLD there was very high prevalence of hakeem/desi medications use (50%). This is perhaps the first study conducted in south Asia amongst RA patient to look for fatty liver, which has generated local data, along with it we looked at the use of Hakeem/Desi medicine use and presence of metabolic syndrome and calculated CVD risk score as well.

Limitations of the study {#sec2-1}
------------------------

It included cumulative dose of methotrexate couldn't be calculated as no electronic records of prescribed DMARD's are available and patients also tend to loose records and miss the doses in between, sample size is small we can't generalize the study results.

CONCLUSION {#sec1-5}
==========

Fatty liver disease not only hampers the ongoing efforts to achieve remission with escalation of conventional dmards and introduction of biological dmards and may enhances the risk of cardiovascular events, which is already high in RA. Regular monitoring with LFT's and ultrasonography is required at the start of treatment and during follow up.
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